178 related articles for article (PubMed ID: 38502296)
1. Outcomes of Hepatic Artery-Based Therapies and Systemic Multiagent Chemotherapy in Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis.
Sugumar K; Stitzel H; Wu V; Bajor D; Chakrabarti S; Conces M; Henke L; Lumish M; Mahipal A; Mohamed A; Winter JM; Hardacre JM; Ammori JB; Selfridge JE; Ocuin LM
Ann Surg Oncol; 2024 Jul; 31(7):4413-4426. PubMed ID: 38502296
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
[TBL] [Abstract][Full Text] [Related]
3. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
4. Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.
Pernot S; Pellerin O; Mineur L; Monterymard C; Smith D; Lapuyade B; Gallois C; Khemissa Akouz F; De Baere T; Tougeron D; Thirot-Bidault A; Audemar F; Simon M; Lecaille C; Louafi S; Lepage C; Ducreux M; Taieb J
Dig Liver Dis; 2022 Mar; 54(3):324-330. PubMed ID: 35027324
[TBL] [Abstract][Full Text] [Related]
5. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
6. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA
Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165
[TBL] [Abstract][Full Text] [Related]
7. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
[TBL] [Abstract][Full Text] [Related]
8. Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol.
Boilève A; Maillard A; Wagner M; Dromain C; Laurent C; Dupont Bierre E; Le Sourd S; Audemar F; Ulusakarya A; Guerin-Meyer V; Smisth D; Pezzella V; De Baere T; Goere D; Gelli M; Taieb J; Boige V
BMC Cancer; 2020 Jan; 20(1):74. PubMed ID: 32000724
[TBL] [Abstract][Full Text] [Related]
9. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
[TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
Seki H; Ozaki T; Shiina M
Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
[TBL] [Abstract][Full Text] [Related]
11. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI
J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816
[TBL] [Abstract][Full Text] [Related]
12. Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
Link KH; Kornmann M; Leder G; Pillasch AF; Sunelaitis E; Schatz M; Pressmar J; Beger HG
Gan To Kagaku Ryoho; 1999 Feb; 26(3):269-81. PubMed ID: 10065089
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.
Bolton JS; O'Connell MJ; Mahoney MR; Farr GH; Fitch TR; Maples WJ; Nagorney DM; Rubin J; Fuloria J; Steen PD; Alberts SR
Clin Colorectal Cancer; 2012 Mar; 11(1):31-7. PubMed ID: 21729678
[TBL] [Abstract][Full Text] [Related]
14. Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
Boilève A; De Cuyper A; Larive A; Mahjoubi L; Najdawi M; Tazdait M; Gelli M; Tselikas L; Smolenschi C; Malka D; Pignon JP; Ducreux M; Boige V
Eur J Cancer; 2020 Oct; 138():89-98. PubMed ID: 32871526
[TBL] [Abstract][Full Text] [Related]
15. Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial.
Liu Y; Chang W; Zhou B; Wei Y; Tang W; Liang F; Chen Y; Yan Z; Lv M; Ren L; Xu J
Br J Surg; 2021 Apr; 108(4):373-379. PubMed ID: 33611431
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32).
Kusano M; Aoyama T; Okabayashi K; Hirata K; Tsuji Y; Nakamori S; Asahara T; Ohashi Y; Yoshikawa T; Sakamoto J; Oba K; Saji S
J Cancer Res Ther; 2018 Sep; 14(Supplement):S761-S766. PubMed ID: 30249900
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis.
Zacharias AJ; Jayakrishnan TT; Rajeev R; Rilling WS; Thomas JP; George B; Johnston FM; Gamblin TC; Turaga KK
PLoS One; 2015; 10(10):e0139940. PubMed ID: 26448327
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure.
Sato Y; Inaba Y; Ura T; Nishiofuku H; Yamaura H; Kato M; Takahari D; Tanaka T; Muro K
J Gastrointest Cancer; 2018 Jun; 49(2):132-137. PubMed ID: 28058527
[TBL] [Abstract][Full Text] [Related]
19. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
[TBL] [Abstract][Full Text] [Related]
20. Hepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy.
Pilati P; Mammano E; Mocellin S; Tessari E; Lise M; Nitti D
Anticancer Res; 2009 Oct; 29(10):4139-44. PubMed ID: 19846962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
